Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper
| Autor: | Hiroaki Matsumoto, Koji Shiraishi, Haruhito Azuma, Keiji Inoue, Hirotsugu Uemura, Masatoshi Eto, Chikara Ohyama, Osamu Ogawa, Eiji Kikuchi, Hiroshi Kitamura, Nobuo Shinohara, Satoru Takahashi, Toyonori Tsuzuki, Masayuki Nakagawa, Yoshifumi Narumi, Hiroyuki Nishiyama, Tomonori Habuchi, Shiro Hinotsu, Yasuhisa Fujii, Kiyohide Fujimoto, Hiroyuki Fujimoto, Takashi Mizowaki, Hideyasu Matsuyama, Nobuyuki Sekita, Hiroshi Juri, Yuki Inada, Takashige Abe, Hideo Fukuhara, Yukio Naya, Satoshi Mutoh, Shigehisa Kitano, Takashi Kobayashi, Teruo Inamoto, Makito Miyake, Junichi Inokuchi, Tetsutaro Hayashi, Takahiro Kojima, Katsuyoshi Hashine, Toshiki Kijima, Yoshiyuki Matsui, Tomohiko Hara, Shingo Hatakeyama, Yoshiaki Yamamoto, Shintaro Narita, Tomoyasu Tsushima, Takafumi Miura, Takeru Shiroiwa, Mototsugu Oya, Momokazu Gotoh, Haruki Kume, Yasutomo Nasu, Katsuyuki Tsunemune |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Bladder cancer business.industry Urology General surgery medicine.medical_treatment Urinary system 030232 urology & nephrology Medical information Evidence-based medicine medicine.disease Cystectomy Clinical Practice 03 medical and health sciences 0302 clinical medicine Japan Urinary Bladder Neoplasms 030220 oncology & carcinogenesis medicine Position paper Humans business Grading (tumors) |
| Zdroj: | International journal of urology : official journal of the Japanese Urological AssociationReferences. 27(5) |
| ISSN: | 1442-2042 |
| Popis: | The Clinical Practice Guidelines for Bladder Cancer edited by the Japanese Urological Association were first published in 2009 and a revised edition was released in 2015. Four years has passed since the 2015 edition, and the clinical practice environment surrounding bladder cancer has drastically changed during that time. The main changes include: (i) insurance coverage of a new diagnostic method for non-muscle-invasive bladder cancer; (ii) insurance coverage of an immune checkpoint inhibitor in advanced and metastatic bladder cancer; and (iii) advances in robot-assisted radical cystectomy as a minimally invasive treatment for muscle-invasive bladder cancer. A paradigm shift in bladder cancer diagnosis and treatment is occurring day by day. Therefore, in this 2019 edition, while dealing with the above changes, we carefully selected clinical questions with clear evidence and included other clinically important points in the general statement. We also added a new chapter on rare cancers of the urinary tract. As a new method for the evaluation of study evidence level, we introduce "The Grading of Recommendations Assessment, Development and Evaluation" system modified to Japanese by the Medical Information Network Distribution Service. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text